Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, mainly because of a lack of prospective randomized studies, due to difficulties in enrolling patients. Between 2002 and 2006, 54 untreated HL patients, aged between 65 and 80 years and considered 'non-frail' according to a comprehensive geriatric evaluation, were enrolled into a phase III randomized trial to compare a reduced-intensity regimen (vinblastine, cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone, bleomycin; VEPEMB) with standard ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Primary endpoint was progression-free survival (PFS). Seventeen patients were in early stage (I-IIA), while 37 were advanced stage. Median age was 72 years and median follow-up was 76 months. Five-year PFS rates were 48% vs. 70% [adjusted Hazard ratio (HR) = 2·19, 95% confidence interval (CI) = 0·94-5·10, P = 0·068] and 5-year overall survival (OS) rates were 63% vs. 77% (adjusted HR = 1·67, 95% CI = 0·69-4·03, P = 0·254) for VEPEMB compared to ABVD. Overall treatment-related mortality was 4%. World Health Organization grade 4 cardiac and lung toxicity occurred in four patients treated with ABVD versus no cases in the VEPEMB arm. Standard ABVD regimen resulted in better PFS and OS than the VEPEMB, although the differences were not statistically significant. The low toxicity of both treatments was probably attributable to stringent selection of patients based on a Comprehensive Geriatric Assessment that excluded frail patients.

Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) / Zallio, Francesco; Tamiazzo, Stefania; Monagheddu, Chiara; Merli, Francesco; Ilariucci, Fiorella; Stelitano, Caterina; Liberati, Anna Marina; Mannina, Donato; Vitolo, Umberto; Angelucci, Emanuele; Rota Scalabrini, Delia; Vallisa, Daniele; Bellei, Monica; Bari, Alessia; Ciccone, Giovannino; Salvi, Flavia; Levis, Alessandro. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 172:6(2016), pp. 879-888. [10.1111/bjh.13904]

Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)

Bellei, Monica;Bari, Alessia;
2016

Abstract

Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, mainly because of a lack of prospective randomized studies, due to difficulties in enrolling patients. Between 2002 and 2006, 54 untreated HL patients, aged between 65 and 80 years and considered 'non-frail' according to a comprehensive geriatric evaluation, were enrolled into a phase III randomized trial to compare a reduced-intensity regimen (vinblastine, cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone, bleomycin; VEPEMB) with standard ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Primary endpoint was progression-free survival (PFS). Seventeen patients were in early stage (I-IIA), while 37 were advanced stage. Median age was 72 years and median follow-up was 76 months. Five-year PFS rates were 48% vs. 70% [adjusted Hazard ratio (HR) = 2·19, 95% confidence interval (CI) = 0·94-5·10, P = 0·068] and 5-year overall survival (OS) rates were 63% vs. 77% (adjusted HR = 1·67, 95% CI = 0·69-4·03, P = 0·254) for VEPEMB compared to ABVD. Overall treatment-related mortality was 4%. World Health Organization grade 4 cardiac and lung toxicity occurred in four patients treated with ABVD versus no cases in the VEPEMB arm. Standard ABVD regimen resulted in better PFS and OS than the VEPEMB, although the differences were not statistically significant. The low toxicity of both treatments was probably attributable to stringent selection of patients based on a Comprehensive Geriatric Assessment that excluded frail patients.
2016
13-gen-2016
172
6
879
888
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) / Zallio, Francesco; Tamiazzo, Stefania; Monagheddu, Chiara; Merli, Francesco; Ilariucci, Fiorella; Stelitano, Caterina; Liberati, Anna Marina; Mannina, Donato; Vitolo, Umberto; Angelucci, Emanuele; Rota Scalabrini, Delia; Vallisa, Daniele; Bellei, Monica; Bari, Alessia; Ciccone, Giovannino; Salvi, Flavia; Levis, Alessandro. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 172:6(2016), pp. 879-888. [10.1111/bjh.13904]
Zallio, Francesco; Tamiazzo, Stefania; Monagheddu, Chiara; Merli, Francesco; Ilariucci, Fiorella; Stelitano, Caterina; Liberati, Anna Marina; Mannina, Donato; Vitolo, Umberto; Angelucci, Emanuele; Rota Scalabrini, Delia; Vallisa, Daniele; Bellei, Monica; Bari, Alessia; Ciccone, Giovannino; Salvi, Flavia; Levis, Alessandro
File in questo prodotto:
File Dimensione Formato  
34.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 348.84 kB
Formato Adobe PDF
348.84 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1148607
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 23
social impact